Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Stock Price & Analysis
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) closed at USD 58.79 on Thursday, October 22, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 58.79; the Oct 22, 2026 session ranged USD 58–58 on volume of 100 shares. Market capitalization is $12.23B, with a 52-week range of USD 55.88–65.44 (PNK). Source: Nexqual, retrieved October 23, 2026 at 16:41 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RCDTF.md
Key facts (RCDTF)
- Analysts: None.
- Total return with dividends: 1Y -8.1% vs S&P 500 +14.6%; 5Y +9.7% vs S&P 500 +77.3%.
- Next earnings: 2026-11-10, EPS estimate USD —, revenue estimate $674M.
Analysts (RCDTF)
Consensus None.
Total return (dividends reinvested) (RCDTF)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -8.1% | +9.7% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | -8.2% | +1.9% |
| Volatility (annualized) | 15.6% | 26.9% |
| Max drawdown | -14.6% (Nov 2025→Apr 2026) | -42.9% (Nov 2021→Sep 2022) |
RCDTF analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | — | — | — | $674.4M | — |
| Next quarter (ends Dec 2026) | — | — | — | $684.8M | — |
| Current fiscal year (ends Dec 2026) | — | — | — | $2.79B | — |
| Next fiscal year (ends Dec 2027) | — | — | — | $3.03B | — |
Key Statistics (as of October 23, 2026 at 16:41 UTC)
| Price | USD 58.79 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 58.79 |
| Open | USD 58 |
| Day Range | USD 58 – 58 |
| 52-Week Range | USD 55.88 – 65.44 |
| Volume | 100 shares |
| Market Cap | $12.23B |
| Exchange | PNK |
Technical Analysis (RCDTF)
Nexqual's technical model rates RCDTF "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 16:41 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 58.25) |
| MACD | 0.18 (positive) |
Analyst Ratings (RCDTF)
Wall Street analysts rate RCDTF "None", per Nexqual as of October 23, 2026 at 16:41 UTC.
| Consensus Rating | None |
|---|
Earnings (RCDTF)
| Next Earnings Date | 2026-11-10 |
|---|---|
| Revenue Estimate | $674.40M |
Source: Nexqual, October 23, 2026 at 16:41 UTC.
Financials & Fundamentals (RCDTF)
| Total Revenue | $2.71B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +8.30% |
| Gross Margin | +71.48% |
| Operating Margin | +29.20% |
| Profit Margin | +18.38% |
| ROE | +24.85% |
| Debt / Equity | 1.09 |
| Current Ratio | 1.26 |
| Total Cash | $391.38M |
| Total Debt | $2.31B |
Source: Nexqual, October 23, 2026 at 16:41 UTC.
Financial Health Score (RCDTF)
Nexqual rates Recordati Industria Chimica e Farmaceutica S.p.A.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 16:41 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 71%, operating 29% (last 12 months) |
| Balance Sheet | Mixed — EUR 391M cash vs EUR 2.31B debt |
| Cash Flow | Solid — Operating cash flow EUR 645M (TTM) |
| Efficiency | Strong — ROE 25%, ROA 9.8% |
Ownership (RCDTF)
| Insider Ownership | +46.82% |
|---|---|
| Institutional Ownership | +33.22% |
| Shares Outstanding | 208.00M |
| Float | 101.87M |
Source: Nexqual, October 23, 2026 at 16:41 UTC.
Leadership (RCDTF)
Recordati Industria Chimica e Farmaceutica S.p.A. is led by Robert Koremans, CEO & Director, per Nexqual as of October 23, 2026 at 16:41 UTC.
| CEO & Director | Robert Koremans |
|---|---|
| Executive Director | Cathrin Petty |
| Executive Director | Giampiero Mazza |
| Chief Financial Officer | Michael McClellan |
| Group Communications Director | Laura Conti |
Major Backers & Investors (RCDTF)
Notable institutional backers of Recordati Industria Chimica e Farmaceutica S.p.A. include Fidelity, AIM Intl Mutual Fd.s -Invesco Intl Small-Mid Company Fd., according to Nexqual as of October 23, 2026 at 16:41 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 2.94% |
| AIM Intl Mutual Fd.s -Invesco Intl Small-Mid Company Fd. | 0.31% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.24% |
| BlackRock | 0.35% |
Source: Nexqual, October 23, 2026 at 16:41 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GRFS | Grifols, S.A. | USD 7.55 | ▲ 1.28% |
| BIIB | Biogen Inc. | USD 250.61 | ▼ 1.27% |
| OGN | Organon & Co. | USD 13.76 | ▲ 0.07% |
| SNY | Sanofi | USD 41.51 | ▼ 1.08% |
| GSK | GSK plc | USD 50.64 | ▼ 1.11% |
| BMY | Bristol-Myers Squibb Company | USD 61.8 | ▼ 1.9% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 16:41 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt